Suzhou, China, September 15th, 2025—CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that one of its autoimmune and inflammation pipeline CS2015 (OX40L/TSLP bispecific antibody) has been accepted for an in-person, ePoster - Meet the Author, presentation during the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6 to 10.
CS2015 is a potential first-in-class/best-in-class bispecific antibody targeting both OX40L and TSLP and concurrently blocking two key ligands in Th2-mediated inflammatory signaling pathways. This novel mechanism provides a strategic approach for Type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), etc.
The presentation schedule is as follows:
Title: CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation Diseases
Abstract ID: 8079
Presentation Type: ePoster display & 15-min in-person presentation (ePoster ID: R377)
Date & Time: Friday, November 7, 3:05 PM ET
* The abstract and ePoster will be available on the ACAAI website on November 6.
About CStone
CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.
For more information about CStone, please visit: www.cstonepharma.com.
IR contact: ir@cstonepharma.com
PR contact: pr@cstonepharma.com
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.
Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.
